Cover Image

Prognostic significance of pre‐treatment immune‐inflammation biomarkers in anal cancer: A study combining real‐world data and a meta‐analysis

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Karen Lycke Wind, Johanne Hollands Steffensen, Anne Vittrup Jakobsen, Camilla Kronborg, Karen‐Lise Garm Spindler
Format:	Artículo Open Access
Published:	Wiley 2025
Subjects:	International Journal of Cancer
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The prognostic value of cell‐free DNA dynamics during chemoradiotherapy in squamous cell carcinomas of the anus
by: Anne Vittrup Jakobsen, et al.
Published: (2025)

Prognostic significance of systemic immune‐inflammation index in patients with nonfunction pancreatic neuroendocrine tumor undergoing surgical resection
by: Guanhua Chen, et al.
Published: (2024)

Novel biomarker significantly improves diagnostic accuracy for nasopharyngeal cancer
by: Mary Beth Nierengarten
Published: (2024)

Prognostic value of cardiovascular magnetic resonance in immune checkpoint inhibitor‐associated myocarditis: A systematic review and meta‐analysis
by: Wenhua Song, et al.
Published: (2024)

Self‐collected versus clinician‐collected anal swabs for anal cancer screening: A systematic review and meta‐analysis
by: Clare E. F. Dyer, et al.
Published: (2024)

Impact of inflammation and the immune system on hepatocellular carcinoma recurrence after hepatectomy
by: Sha She, et al.
Published: (2024)

Pan‐immune‐inflammation value predicts immunotherapy response and reflects local antitumor immune response in rectal cancer
by: Qianyu Wang, et al.
Published: (2024)

Body composition change indices combined with Prognostic Nutritional Index predicts the clinical outcomes of patients with gastric cancer treated with immune checkpoint inhibitor
by: Guiming Deng, et al.
Published: (2024)

Efficacy and safety of novel immune checkpoint inhibitor‐based combinations versus chemotherapy as first‐line treatment for patients with extensive‐stage small cell lung cancer: A network meta‐analysis
by: Chuang Yang, et al.
Published: (2024)

Prognostic significance of glucose‐lipid metabolic index in pancreatic cancer patients with diabetes mellitus
by: Hailiang Wang, et al.
Published: (2024)

Lipocalin‐2 as a prognostic biomarker and its association with systemic inflammation in small cell lung cancer
by: Se‐Il Go, et al.
Published: (2024)

Prognostic implications of combining EGFR‐TKIs and radiotherapy in Stage IV lung adenocarcinoma with 19‐Del or 21‐L858R mutations: A real‐world study
by: Shuai Liang, et al.
Published: (2024)

A novel nomogram based on inflammation biomarkers for predicting radiation cystitis in patients with local advanced cervical cancer
by: Jie Lin, et al.
Published: (2024)

Real‐world study of palbociclib combined with endocrine therapy for patients with metastatic breast cancer: A comparison of subsequent treatment patterns and HER2 expression analysis
by: Xu Liang, et al.
Published: (2024)

Comments on “International anal neoplasia society's consensus guidelines for anal cancer screening”
by: Massimiliano Mistrangelo, et al.
Published: (2025)

Unveiling the impact of chemotherapy in patients with breast cancer: A longitudinal study on peripheral inflammation, multimodal magnetic resonance imaging, and cognition
by: Rob Colaes, et al.
Published: (2025)

Interobserver agreement in the interpretation of anal cytology
by: Maria Benevolo, et al.
Published: (2024)

Anti‐Müllerian hormone for assessing ovarian toxicity of cancer treatment in young women: It’s complicated
by: Kimia Sorouri, et al.
Published: (2025)

Impact of resistance training on inflammatory biomarkers and associations with treatment outcomes in colon cancer
by: Seohyuk Lee, et al.
Published: (2025)

Scoring system for diagnosis and pretreatment risk assessment of neuroblastoma using urinary biomarker combinations
by: Hizuru Amano, et al.
Published: (2024)

Prognostic impact of extramedullary disease in acute myeloid leukemia: A meta‐analysis
by: Yufan Lin, et al.
Published: (2025)

Automated CT quantification of interstitial lung abnormality in patients with resectable stage I non‐small cell lung cancer: Prognostic significance
by: Jae Ho Chung, et al.
Published: (2024)

Immune checkpoint inhibitors combined with anti‐angiogenic therapy as second‐ or further‐line treatment for small cell lung cancer: Efficacy, safety, and prognostic biomarkers
by: Tong Chen, et al.
Published: (2025)

Genetic and immune identification and functional analysis of TRPM8 as a potential biomarker for pancreatic adenocarcinoma proliferation
by: Sen Qiao, et al.
Published: (2024)

Blood‐based biomarkers in soft tissue sarcoma: Implications for immune checkpoint inhibitor therapy
by: Brie‐Anne Mannah, et al.
Published: (2025)

Prediction performance comparison of biomarkers for response to immune checkpoint inhibitors in advanced non‐small cell lung cancer
by: Jie Zhao, et al.
Published: (2024)

Inconsistency in steroid use as antiemetics in clinical trial protocols involving immune checkpoint inhibitors combined with chemotherapy
by: Soh Mee Park, et al.
Published: (2024)

New FDA approval for immunotherapy‐based combination treatment for unresectable or metastatic liver cancer
by: Mary Beth Nierengarten
Published: (2025)

Prognostic significance of circulating tumor cells and tumor related transcripts in small cell lung cancer: A step further to clinical implementation
by: Eva Welsch, et al.
Published: (2024)

Identification ofPSMD11as a novel cuproptosis‐ and immune‐related prognostic biomarker promoting lung adenocarcinoma progression
by: Qiumin Huang, et al.
Published: (2024)

Adenocarcinoma of the esophagus and gastroesophageal junction: The evolving treatment landscape for locally advanced and metastatic disease in the era of immune checkpoint inhibitors and biomarker‐driven therapeutics
by: Laura V. M. Baum, et al.
Published: (2026)

“Other” high‐risk HPV: Challenges in anal cancer screening
by: Margaret L. Compton
Published: (2025)

Development and validation of a nomogram for predicting immune‐related pneumonitis after sintilimab treatment
by: Baohui Hong, et al.
Published: (2024)

A real‐world data analysis of the impact of clonal hematopoiesis of indeterminate potential on therapeutic efficacy and adverse events of immune checkpoint inhibitors
by: Takamasa Fujita, et al.
Published: (2026)

Impact of immune checkpoint inhibitors on survival outcomes in advanced gastric cancer in Japan: A real‐world analysis
by: Toru Kadono, et al.
Published: (2024)

The association of nutritional and inflammatory biomarkers with overall survival in patients with non‐small‐cell lung cancer treated with immune checkpoint inhibitors
by: I. M. Horstman, et al.
Published: (2024)

Efficacy of first‐line immune checkpoint inhibitor and anti‐angiogenic agent combination therapy for Kirsten rat sarcoma viral antigen‐mutant advanced non‐small‐cell lung cancer: a systematic review and network meta‐analysis
by: Akinari Tsukada, et al.
Published: (2024)

Enhanced CTLA‐4 blockade anti‐tumor immunity with APG‐157 combination in a murine head and neck cancer
by: Daniel Sanghoon Shin, et al.
Published: (2024)

Optimizing treatment for platinum‐resistant ovarian clear cell carcinoma: Efficacy of gemcitabine and combination therapy with bevacizumab
by: Yasunori Yoshino, et al.
Published: (2025)

Guanylate binding protein 5 is an immune‐related biomarker of oral squamous cell carcinoma: A retrospective prognostic study with bioinformatic analysis
by: Masayo Hasegawa, et al.
Published: (2024)